Media Articles Related to Depocyt (Cytarabine)
Meningitis B Vaccine Falls Short of Expectations
Source: MedicineNet Aches, Pain, Fever Specialty [2016.07.21]
Title: Meningitis B Vaccine Falls Short of Expectations
Category: Health News
Created: 7/20/2016 12:00:00 AM
Last Editorial Review: 7/21/2016 12:00:00 AM
Source: MedicineNet Hand-Foot-And-Mouth Syndrome Specialty [2015.07.16]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/16/2015 12:00:00 AM
Anti-Inflammatory Helps Treat Bacterial Meningitis: Study
Source: MedicineNet dexamethasone oral Specialty [2010.09.30]
Title: Anti-Inflammatory Helps Treat Bacterial Meningitis: Study
Category: Health News
Created: 9/29/2010 6:10:00 PM
Last Editorial Review: 9/30/2010
Early warning signs for meningitis in children identified
Source: The Doctors Lounge - Infections
A number of early symptoms for meningococcal disease in children could substantially speed up diagnosis.
Published Studies Related to Depocyt (Cytarabine)
Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose
cytarabine and placebo in older adults with untreated acute myeloid leukemia. 
Improving outcomes in older adults with acute myeloid leukemia remains a
formidable challenge. Lintuzumab (SGN-33; HuM195) is a humanized monoclonal
antibody directed against CD33, which is expressed on the majority of myeloblasts
in acute myeloid leukemia... These results confirm that lintuzumab
in combination with low-dose cytarabine did not prolong survival and that
low-dose cytarabine remains a valid comparator for trials of non-intensive
therapies in older patients with acute myeloid leukemia, regardless of
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. [2011.08.18]
To assess the value of administering timed-sequential chemotherapy (TSC; 2 therapeutic sequences separated by a 4-day interval-free chemotherapy) or high-dose cytarabine (HDAraC) cycles in consolidation therapy for acute myeloid leukemia (AML), 459 patients 15 to 50 years of age were enrolled in the prospective randomized Acute Leukemia French Association-9802 trial...
Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. [2011.07.01]
PURPOSE: To assess the optimal cumulative dose of cytarabine for treatment of young adults with acute myeloid leukemia (AML) within a prospective multicenter treatment trial... CONCLUSION: In young adults with AML receiving intermediate-dose cytarabine induction, intensification of the cytarabine dose beyond 12 g/m(2) within first consolidation did not improve treatment outcome.
Cytarabine dose for acute myeloid leukemia. [2011.03.17]
BACKGROUND: Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated... CONCLUSIONS: Induction therapy with cytarabine at the lower dose already produced maximal antileukemic effects for all response end points, suggesting a plateau in the dose-response relationship above this dose level. High-dose cytarabine results in excessive toxic effects without therapeutic benefit. (Netherlands Trial Register number, NTR230.).
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. [2011.02.24]
We conducted a prospective randomized study to assess the optimal postremission therapy for adult acute myeloid leukemia in patients younger than 65 years in the first complete remission. A total of 781 patients in complete remission were randomly assigned to receive consolidation chemotherapy of either 3 courses of high-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days) alone or 4 courses of conventional standard-dose multiagent chemotherapy (CT) established in the previous JALSG AML97 study...
Clinical Trials Related to Depocyt (Cytarabine)
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis [Terminated]
- To determine the safety, tolerability and maximum tolerated dose (MTD) of oral
temozolomide using a 7 days on and 7 days off regimen combined with intrathecal liposomal
cytarabine (DepoCyt) in patients with neoplastic meningitis from solid tumors and systemic
Depocyt® With Sorafenib in Neoplastic Meningitis [Terminated]
The purpose of this study is to determine the tolerability and side effects of oral
sorafenib in combination with intrathecal DepoCyt.
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma [Terminated]
Current treatments for Glioblastoma Multiforme (GBM), the most common and malignant primary
brain tumor are inadequate and as such, the median survival for most patients with GBM is on
the order of months, even after cytoreductive surgery, radiation and chemotherapy. This
study aims to develop a new treatment for GBM by suppressing glial progenitor cells that
surround the ventricular system in patients with these aggressive tumors because it is these
regions that appear to act as an incubator for future recurrences resulting in patient
death. Considering the lack of significant treatment options for patients with this
uniformly fatal disease, this is an important translational clinical study to perform.
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) [Suspended]
- Replacement of intrathecal Triple (methotrexate, cytarabine, prednisolone) with
intrathecal liposomal cytarabine and prednisolone during maintenance therapy will
decrease the CNS relapse rate in high-risk ALL patients.
- Both acute and long-term toxicity are equal in both treatment arms.
DepoCyt for Active Lymphomatous or Leukemic Meningitis [Terminated]
The purpose of this study is to determine the response rate of lymphomatous meningitis or
leukemic meningitis to DepoCyt. The safety of DepoCyt, the number of people who respond
well to the study drug, and the response of symptoms to the study drug will also be
Reports of Suspected Depocyt (Cytarabine) Side Effects
Mucosal Inflammation (7),
Hepatic Enzyme Increased (6),
Pneumocystis Jiroveci Pneumonia (5),
Herpes Simplex (5),
Dysarthria (5), more >>